News and Events
- SBFE research fellow Xiaohui Lin receives the MSCA DOROTHY COFUND award
- Upskill with UCD’s engineering micro-credentials
- Minister O’Donovan announces funding boost for early career researchers
- Recent Lab visit by UCD Engineering & Architecture to Sheffield University Diamond Centre
- UCD Stormwater Runoff Research featured in Nicola Haines Team
- Madeleine Lowery among UCD Researchers recognised in SFI Frontiers for the Future Awards
- UCD’s LaNua Medical Wins Big Ideas Award at Enterprise Ireland’s Start-Up Day 2024
- Robotics Competition
- Congratulations to All the Winners of this years NovaUCD Awards
- Irish National Doctoral Research Cohort on Floating Offshore Wind Dynamic Cables is formed
- UCD and Northeastern University extend and deepen long-standing partnership with five collaborative research projects
- EPA announces €14.3M in new research funding
- Arup Scholarship Awards 2024
- UCD names new Vice-President for Equality, Diversity and Inclusion
- Project promoting safe staffing in the healthcare system wins UCD Research Impact Competition
- VOICE Project Launches to Shape Tomorrow's Sustainability
- Archives
- 2023 News Archive
- 2022 News Archive
- 2021 News Archive
- Barry Brophy was featured in the Sunday Independent last weekend with an article on sports communication
- Samantha L. Martin-McAuliffe has been named a Mellon History Teaching Fellow at Dumbarton Oaks
- FOREIGN EXCHANGE: Conversations on Architecture Here and Now
- Go Eve: EV charging start-up wins UCD’s 2021 Start-Up of the Year
- Professor Anding Zhu elevated to IEEE Fellow
- Symposium: Inclusive Teaching & Learning Case Studies in Engineering, Architecture & Affiliated Disciplines
- Ireland’s first satellite measuring up at ESA for Space Week
- UCD Silicon Quantum Computing Spin-Out Receives Multimillion Euro Venture Capital Investment
- Prof Orla Feely delivers Presidential Address to Engineers Ireland on Ireland’s industrial transformation
- New EU Research Project “Screen4Care”: Accelerating Diagnosis for Rare Disease Patients Through Genetic Newborn Screening and Artificial Intelligence
- September 2021 Conferring Ceremony
- UCD’s Masters in Engineering Management (MEM) announces a big reduction in the requirement for on-campus attendance
- Early-Stage Venture Developing a Software Platform to Augment Human Memory Wins NovaUCD’s 2021 Student Enterprise Competition
- UCD project aiming to make dairy farms climate neutral awarded €2m Future Innovator Prize
- UCD Professor Orla Feely inaugurated as President of Engineers Ireland
- 2021 Conferring Ceremony
- Irish Researchers Win Prestigious ICE Publishing Award
- Eco-friendly biological energy harvesting solutions from University College Dublin addresses real-time damage in water pipelines
- Prof Lizbeth Goodman named in the G100 Group of Global Leaders working for Women’s Equity and Transformational Change
- Spotlight on Research: Cheryl L’Hirondelle
- UCD Engineers Among Winners of NovaUCD’s 2021 Innovation Awards
- UCD Teaching and Learning Awards
- Three Case Studies from Engineering and Architecture runners-up in 2020 UCD Impact Competition
- Earth Talks: Ravindranathan Thampi
- Two Winners of the Best Innovative Concept Detail Design
- Meet the 2021 Smartlab Winner of the Governor General’s Awards in Visual and Media Arts
- UCD teams shortlisted for SFI's €4m Future Innovator Prize challenge
- European researchers collaborate to prevent risks to transport infrastructure
- MaREI Award
- 2020 News Archive
- 2019 News Archive
- 2018 News Archive
- 2017 News Archive
- 2016 News Archive
- Building the State
- A Centenary Celebration
New EU Research Project “Screen4Care”: Accelerating Diagnosis for Rare Disease Patients Through Genetic New-born Screening and Artificial Intelligence?
Thursday, 30 November, 2023
UCD leads on Patient Engagement, Impact and Dissemination for Scrren4Care, with a new virtual patient platform and virtual clinics designed by PI Professor Lizbeth Goodman for the Inclusive Design Research Centre in MME.
The international consortium aims to tackle the major hurdle for rare disease patients – the lengthy and convoluted diagnosis journey – via an innovative research approach based on two central pillars: genetic new-born screening and artificial intelligence (AI)-based tools.
Ferrara, Italy, 1 October 2021 – Today an international public-private consortium of 35 partners announced the launch of Screen4Care – a research project that aims to significantly shorten the time required for rare disease diagnosis and efficient intervention by utilising genetic new-born screening and advanced analysis methods such as machine learning. The project will run for a period of five years with a total budget of EUR 25 million provided by the Innovative Medicines Initiative (IMI 2 JU), a joint undertaking of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
There are more than 7,000 known rare diseases, conditions that affect one, or less than one, person in 2,000. These conditions, which collectively impact an estimated 27-36 million people across the EU and will affect one in 17 people during their lifetime, are often severe, multisystemic chronic diseases that put patients at risk of permanent organ damage and degeneration. Patients typically face an arduous journey to proper diagnosis, enduring on average eight years of countless doctor’s consultations, misdiagnoses and ineffective treatments. Lengthy diagnosis journeys place a heavy burden on patients, their families and society. They also hinder swift intervention – such as appropriate treatments or enrolment in clinical trials – and patient empowerment, realised through strategies such as lifestyle adjustments, family planning, genetic counselling and coping with the psychosocial and/or financial consequences of the condition.
Screen4Care will use a multi-pronged strategy to shorten the time to diagnosis and treatment for patients with rare diseases:
- Genetic new-born screening: The project will drive new-born screening (using genetic testing and related advanced genomic technologies), which is anticipated to be an effective tool for early diagnosis given that approximately 72% of rare diseases have a genetic cause and 70% of rare disease patients are children.
- AI-based tools: The project will design and develop new AI algorithms to identify patients at early disease onset via electronic health records and develop a repository of AI ‘symptom checkers’ to help patients who are in the midst of their diagnosis journeys – both supporting symptom-based diagnosis later in life.
“Screen4Care has the potential to help patients benefit from precision diagnostics that lead to better care, meaningful hospital visits and a better overall quality of life – and to help strengthen healthcare systems through novel diagnostic tools and a resource-efficient technological infrastructure”, said Alessandra Ferlini, Associate Professor of the Department of Medical Sciences, and Head of the Medical Genetics Unit at the University of Ferrara, Italy, and Scientific Coordinator of the project. “Of particular importance to the project is the active involvement of stakeholders to help shape the design and decisions for value-based healthcare.”
“Because of the nature of their conditions, rare disease patients and their families commonly experience delays to diagnosis, which can lead to serious consequences for their health as well as their ability to plan for their future”, said Nicolas Garnier, Doctor in Experimental Medicine, Director of Patient Advocacy, Rare Disease Global Product Development at Pfizer, and Project Lead on behalf of EFPIA. “We therefore challenged ourselves to address this most pressing issue: accelerating patients’ path to diagnosis.”
Building a digital infrastructure to foster exchange among physicians, patients, relatives and caretakers
In addition to its goal of developing the core early-diagnosis system, Screen4Care aims to establish a digital infrastructure and ecosystem to engage patients, parents of new-born's and caregivers as equal decision-makers in the diagnosis process. The ecosystem will provide an open innovation platform, which allows for continuous data collection and information exchange, aiding the development of next-generation diagnostics and enabling physicians, patients and relatives to make informed decisions at an earlier stage. Screen4Care proposes that this will contribute to minimised disease progression, improved patient health and quality of life and an optimised use of healthcare resources.
The Screen4Care team comprises 21 academic partners led by the University of Ferrara, nine industrial project partners led by Pfizer, and four small and medium-sized enterprises. It brings together experts in genetics, bioinformatics, data management and standards, imaging for phenotyping, ethics and health preference research, decision-analytic modelling, and cybersecurity. Furthermore, the consortium is complemented by EURORDIS, representing rare disease patients in Europe to promote robust dialogue and ensure the needs and preferences of the rare disease community guide progression of the project. “Screen4Care is dedicated to giving everybody representation at the table”, explained Dr Garnier. “The project’s focus on equity sets it apart, and it is a unique opportunity to effect meaningful, longstanding change for the diverse rare disease community.”
Project Key Facts
Full Name: Screen4Care – Shortening the path to rare disease diagnosis by using new-born genetic screening and digital technologies
Start Date: 1 October 2021
Duration: 5 years
Budget: 25 Mio €
Coordinator: University of Ferrara, Italy
Project Lead: Pfizer Ltd, UK
Website: (opens in a new window)www.screen4care.eu
Project Partners
Austria
- Ludwig Boltzmann Gesellschaft GmbH
- Research Institute AG & Co KG
- SBA Research gemeinnützige GmbH
Bulgaria
- Bulgarian Association for Personalized Medicine
- Bulgarian Association for the Promotion of Education and Science
Czech Republic
- University Karlova- 2nd Faculty of Medicine and Motol University Hospital
Denmark
- Copenhagen Business School
- FindZebra ApS
- Novo Nordisk A/S
- Syddansk University
France
- Eurordis-Rare Diseases Europe
- Lysogene S.A.
- Sanofi-Genzyme
Germany
- Charité - Universitätsmedizin Berlin
- Eurice - European Research and Project Office Gmbh
- Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- Universitätsmedizin Göttingen – Georg-August-Universität Göttingen
- University Hospital Bonn
- University Hospital Erlangen
Ireland
University College Dublin, National University of Ireland (Inclusive Design Research Centre-SMARTlab) the IDRC based in MME is leading the project for UCD
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 101034427. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. www.imi.europa.eu
Israel
- Genoox
Italy
- Consorzio Futuro in Ricerca
- Pediatric Hospital Bambino Gesù
- University of Ferrara
- University of Siena
Spain
- Centro Nacional de Análisis Genómico (CNAG-CRG)
Sweden
- Uppsala University
Switzerland
- F. Hoffmann-La Roche AG
- sitem-insel AG
- Novartis Pharma AG
- Takeda Pharmaceuticals International AG
- University Bern
The Netherlands
- ProQR Therapeutics NV
United Kingdom
- Illumina Cambridge Ltd
- Pfizer Ltd